


Novel immunomodulatory treatment against Hypertriglyceridemia



Background

- High triglyceride levels can contribute to life-threatening pathologies such as metabolic syndrome, heart attack and stroke.

Technology and Advantages

- A novel immunomodulatory therapeutic is developed against a new target not previously linked to triglyceride metabolism
- In preclinical studies, our treatment reduced plasma triglycerides by 50%
- Long-term treatment without side effects

Intellectual Property

- European priority application filed.

Ce-M-M

CeMM is an interdisciplinary research institute of the Austrian Academy of Sciences committed to advancing the understanding of human diseases through basic and biomedical research and is located on the Medical University of Vienna campus.